GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET FORECAST 2018-2026
KEY FINDINGS
The global allergy diagnostic and treatment market is expected to grow at a CAGR of 5.50% over the forecast period of 2018-2026. The growth potential for this market has increased because of various factors such as – an increase in the occurrence of allergies globally, growing environmental pollution and unmet medical needs.
MARKET INSIGHTS
On the basis of diagnosis, the global allergy diagnostic and treatment market is divided into skin testing and antibody testing. Skin testing has been popular in the market because of its quick effectiveness in identifying the allergen affecting the patient as compared to the antibody testing assay, which is used only when the patient is on any medication that might interfere with the result of the skin tests. On the basis of treatment, the market is further classified into treatment by availability, treatment by administration and treatment by products. The market can also be classified on the basis of immunotherapies into subcutaneous administration, sublingual liquid solutions and sublingual tablets.
REGIONAL INSIGHTS
The North American market is expected to show its dominance in the global allergy diagnostic and treatment market over the forecast period, as compared to other regions like Europe, Asia-Pacific, and Rest of World. Major driving factors for this region includes an increase in the prevalence of allergic diseases, growing population, and rising pollution levels. However, the fastest growth is expected from the Asia-Pacific region, due to progressing economies of countries like India, China, Japan, etc.
COMPETITIVE INSIGHTS
The major companies in the allergy diagnostics and treatment market are Beckman Coulter, Allergan Plc, Johnson & Johnson, Hitachi Chemical Diagnostics Inc, and Pfizer, amongst others. The rise in allergic diseases, increase in access and expenditure for medical insurance in the U.S coupled with economic growth in developing countries, easy access to healthcare by individuals and the availability of better diagnostic tools for allergy related problems are all acting as a driving force for the global allergy diagnostic and treatment market.
The global allergy diagnostic and treatment market is expected to grow at a CAGR of 5.50% over the forecast period of 2018-2026. The growth potential for this market has increased because of various factors such as – an increase in the occurrence of allergies globally, growing environmental pollution and unmet medical needs.
MARKET INSIGHTS
On the basis of diagnosis, the global allergy diagnostic and treatment market is divided into skin testing and antibody testing. Skin testing has been popular in the market because of its quick effectiveness in identifying the allergen affecting the patient as compared to the antibody testing assay, which is used only when the patient is on any medication that might interfere with the result of the skin tests. On the basis of treatment, the market is further classified into treatment by availability, treatment by administration and treatment by products. The market can also be classified on the basis of immunotherapies into subcutaneous administration, sublingual liquid solutions and sublingual tablets.
REGIONAL INSIGHTS
The North American market is expected to show its dominance in the global allergy diagnostic and treatment market over the forecast period, as compared to other regions like Europe, Asia-Pacific, and Rest of World. Major driving factors for this region includes an increase in the prevalence of allergic diseases, growing population, and rising pollution levels. However, the fastest growth is expected from the Asia-Pacific region, due to progressing economies of countries like India, China, Japan, etc.
COMPETITIVE INSIGHTS
The major companies in the allergy diagnostics and treatment market are Beckman Coulter, Allergan Plc, Johnson & Johnson, Hitachi Chemical Diagnostics Inc, and Pfizer, amongst others. The rise in allergic diseases, increase in access and expenditure for medical insurance in the U.S coupled with economic growth in developing countries, easy access to healthcare by individuals and the availability of better diagnostic tools for allergy related problems are all acting as a driving force for the global allergy diagnostic and treatment market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ALLERGIC CONJUNCTIVITIS IS BECOMING INCREASINGLY PREVALENT
3.2.2. SKIN PRICK TEST IS THE MOST PREVALENT TYPE OF ALLERGY TESTING
3.2.3. ANTIHISTAMINES TREATMENT HOLDS THE LARGEST MARKET SHARE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. HIGH INCIDENCES AND LARGE ECONOMIC BURDEN OF ALLERGIC DISEASES
4.1.2. RISING ENVIRONMENTAL POLLUTION
4.1.3. HIGH USE OF TOBACCO
4.1.4. PRESENCE OF HIGH UNMET MEDICAL NEEDS
4.2. MARKET RESTRAINTS
4.2.1. STRINGENT REGULATIONS FOR MEDICAL DEVICES
4.2.2. LACK OF AWARENESS ABOUT ALLERGIC DISEASES
4.2.3. HIGH CAPITAL REQUIREMENTS
4.2.4. HIGH DEGREE OF CONSOLIDATION ACTS AS AN ENTRY BARRIER FOR NEW ENTRANTS
4.2.5. ADVERSE EFFECTS OF DRUGS
4.3. MARKET OPPORTUNITIES
4.3.1. ASIAN MARKET PRESENTS HIGH-GROWTH OPPORTUNITIES
4.3.2. RISE IN AWARENESS ABOUT ALLERGIC RHINITIS
4.4. MARKET CHALLENGES
4.4.1. ALTERNATE THERAPIES AND DRUGS
4.4.2. EASY AVAILABILITY OF GENERIC DRUGS
4.4.3. INCREASING HEALTHCARE EXPENDITURE
4.4.4. PATENT EXPIRIES AND COMPETITION FROM GENERIC DRUGS
5. MARKET SEGMENTATION
5.1. MARKET BY TREATMENTS, DIAGNOSTICS AND IMMUNOTHERAPY 2018-2026
5.1.1. TREATMENTS
5.1.1.1. TREATMENT MARKET BY AVAILABILITY
5.1.1.1.1. PRESCRIPTION
5.1.1.1.2. OVER THE COUNTER
5.1.1.2. TREATMENT MARKET BY ADMINISTRATION
5.1.1.2.1. ORAL
5.1.1.2.2. SPRAY
5.1.1.2.3. OCULAR
5.1.1.2.4. TOPICAL
5.1.1.3. TREATMENT MARKET BY PRODUCTS
5.1.1.3.1. ANTIHISTAMINES
5.1.1.3.2. SYMPATHOMIMETICS, DECONGESTANTS AND COMBINATIONS
5.1.1.3.3. CORTICOSTEROIDS
5.1.1.3.4. LEUKOTRIENES
5.1.1.3.5. MAST CELL STABILIZERS
5.1.2. DIAGNOSTICS
5.1.2.1. SKIN TESTING
5.1.2.2. ANTIBODY
5.1.3. IMMUNOTHERAPY
5.1.3.1. SUBCUTANEOUS ADMINISTRATION
5.1.3.2. SUBLINGUAL LIQUID SOLUTIONS
5.1.3.3. SUBLINGUAL TABLETS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY BUYING CRITERIA
6.3. SUPPLY CHAIN ANALYSIS
6.4. PATENT ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. GERMANY
7.2.2. FRANCE
7.2.3. THE UK
7.2.4. RUSSIA
7.2.5. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. AUSTRALIA AND NEW ZEALAND
7.3.5. REST OF APAC
7.4. REST OF WORLD
7.4.1. MIDDLE EAST AND AFRICA
7.4.2. LATIN AMERICA
8. COMPANY PROFILES
8.1. ALLERGAN PLC
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCTION PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVE
8.2. BECKMAN COULTER
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. GLAXOSMITHKLINE PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. HITACHI CHEMICAL DIAGNOSTICS INC.
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. JOHNSON & JOHNSON
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. MERCK
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC MOVES
8.7. PFIZER
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. SANOFI
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. THERMO FISHER DIAGNOSTICS
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. F. HOFFMANN-LA ROCHE LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. MYLAN N.V.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ALLERGIC CONJUNCTIVITIS IS BECOMING INCREASINGLY PREVALENT
3.2.2. SKIN PRICK TEST IS THE MOST PREVALENT TYPE OF ALLERGY TESTING
3.2.3. ANTIHISTAMINES TREATMENT HOLDS THE LARGEST MARKET SHARE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. HIGH INCIDENCES AND LARGE ECONOMIC BURDEN OF ALLERGIC DISEASES
4.1.2. RISING ENVIRONMENTAL POLLUTION
4.1.3. HIGH USE OF TOBACCO
4.1.4. PRESENCE OF HIGH UNMET MEDICAL NEEDS
4.2. MARKET RESTRAINTS
4.2.1. STRINGENT REGULATIONS FOR MEDICAL DEVICES
4.2.2. LACK OF AWARENESS ABOUT ALLERGIC DISEASES
4.2.3. HIGH CAPITAL REQUIREMENTS
4.2.4. HIGH DEGREE OF CONSOLIDATION ACTS AS AN ENTRY BARRIER FOR NEW ENTRANTS
4.2.5. ADVERSE EFFECTS OF DRUGS
4.3. MARKET OPPORTUNITIES
4.3.1. ASIAN MARKET PRESENTS HIGH-GROWTH OPPORTUNITIES
4.3.2. RISE IN AWARENESS ABOUT ALLERGIC RHINITIS
4.4. MARKET CHALLENGES
4.4.1. ALTERNATE THERAPIES AND DRUGS
4.4.2. EASY AVAILABILITY OF GENERIC DRUGS
4.4.3. INCREASING HEALTHCARE EXPENDITURE
4.4.4. PATENT EXPIRIES AND COMPETITION FROM GENERIC DRUGS
5. MARKET SEGMENTATION
5.1. MARKET BY TREATMENTS, DIAGNOSTICS AND IMMUNOTHERAPY 2018-2026
5.1.1. TREATMENTS
5.1.1.1. TREATMENT MARKET BY AVAILABILITY
5.1.1.1.1. PRESCRIPTION
5.1.1.1.2. OVER THE COUNTER
5.1.1.2. TREATMENT MARKET BY ADMINISTRATION
5.1.1.2.1. ORAL
5.1.1.2.2. SPRAY
5.1.1.2.3. OCULAR
5.1.1.2.4. TOPICAL
5.1.1.3. TREATMENT MARKET BY PRODUCTS
5.1.1.3.1. ANTIHISTAMINES
5.1.1.3.2. SYMPATHOMIMETICS, DECONGESTANTS AND COMBINATIONS
5.1.1.3.3. CORTICOSTEROIDS
5.1.1.3.4. LEUKOTRIENES
5.1.1.3.5. MAST CELL STABILIZERS
5.1.2. DIAGNOSTICS
5.1.2.1. SKIN TESTING
5.1.2.2. ANTIBODY
5.1.3. IMMUNOTHERAPY
5.1.3.1. SUBCUTANEOUS ADMINISTRATION
5.1.3.2. SUBLINGUAL LIQUID SOLUTIONS
5.1.3.3. SUBLINGUAL TABLETS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY BUYING CRITERIA
6.3. SUPPLY CHAIN ANALYSIS
6.4. PATENT ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. GERMANY
7.2.2. FRANCE
7.2.3. THE UK
7.2.4. RUSSIA
7.2.5. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. AUSTRALIA AND NEW ZEALAND
7.3.5. REST OF APAC
7.4. REST OF WORLD
7.4.1. MIDDLE EAST AND AFRICA
7.4.2. LATIN AMERICA
8. COMPANY PROFILES
8.1. ALLERGAN PLC
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCTION PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVE
8.2. BECKMAN COULTER
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. GLAXOSMITHKLINE PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. HITACHI CHEMICAL DIAGNOSTICS INC.
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. JOHNSON & JOHNSON
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. MERCK
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC MOVES
8.7. PFIZER
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. SANOFI
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. THERMO FISHER DIAGNOSTICS
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. F. HOFFMANN-LA ROCHE LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. MYLAN N.V.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
LIST OF TABLES
Table 1 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
Table 2 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET BY TREATMENTS, DIAGNOSTICS AND IMMUNOTHERAPY 2018-2026 ($ MILLION)
Table 3 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY AVAILABILITY 2018-2026 ($ MILLION)
Table 4 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY ADMINISTRATION 2018-2026 ($ MILLION)
Table 5 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY PRODUCTS 2018-2026 ($ MILLION)
Table 6 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN DIAGNOSTICS 2018-2026 ($ MILLION)
Table 7 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN IMMUNOTHERAPY 2018-2026 ($ MILLION)
Table 8 NORTH AMERICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 9 EUROPE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 10 ASIA PACIFIC ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 11 REST OF THE WORLD ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 1 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
Table 2 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET BY TREATMENTS, DIAGNOSTICS AND IMMUNOTHERAPY 2018-2026 ($ MILLION)
Table 3 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY AVAILABILITY 2018-2026 ($ MILLION)
Table 4 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY ADMINISTRATION 2018-2026 ($ MILLION)
Table 5 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN TREATMENTS BY PRODUCTS 2018-2026 ($ MILLION)
Table 6 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN DIAGNOSTICS 2018-2026 ($ MILLION)
Table 7 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET IN IMMUNOTHERAPY 2018-2026 ($ MILLION)
Table 8 NORTH AMERICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 9 EUROPE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 10 ASIA PACIFIC ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Table 11 REST OF THE WORLD ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
LIST OF FIGURES
Figure 1 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 2 GLOBAL TREATMENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
Figure 3 GLOBAL TREATMENTS MARKET IN OVER THE COUNTER 2018-2026 ($ MILLION)
Figure 4 GLOBAL TREATMENTS MARKET IN ORAL 2018-2026 ($ MILLION)
Figure 5 GLOBAL TREATMENTS MARKET IN SPRAY 2018-2026 ($ MILLION)
Figure 6 GLOBAL TREATMENTS MARKET IN OCULAR 2018-2026 ($ MILLION)
Figure 7 GLOBAL TREATMENTS MARKET IN TOPICAL 2018-2026 ($ MILLION)
Figure 8 GLOBAL TREATMENTS MARKET IN ANTIHISTAMINES 2018-2026 ($ MILLION)
Figure 9 GLOBAL TREATMENTS MARKET IN SYMPATHOMIMETICS, DECONGESTANTS AND COMBINATIONS 2018-2026 ($ MILLION)
Figure 10 GLOBAL TREATMENTS MARKET IN CORTICOSTEROIDS 2018-2026 ($ MILLION)
Figure 11 GLOBAL TREATMENTS MARKET IN LEUKOTRIENES 2018-2026 ($ MILLION)
Figure 12 GLOBAL TREATMENTS MARKET IN MAST CELL STABILIZERS 2018-2026 ($ MILLION)
Figure 13 GLOBAL DIAGNOSTICS MARKET IN SKIN TESTING 2018-2026 ($ MILLION)
Figure 14 GLOBAL TREATMENTS MARKET IN ANTIBODY 2018-2026 ($ MILLION)
Figure 15 GLOBAL TREATMENTS MARKET IN SUBCUTANEOUS ADMINISTRATION 2018-2026 ($ MILLION)
Figure 16 GLOBAL TREATMENTS MARKET IN SUBLINGUAL LIQUID SOLUTIONS 2018-2026 ($ MILLION)
Figure 17 GLOBAL TREATMENTS MARKET IN SUBLINGUAL TABLETS 2018-2026 ($ MILLION)
Figure 18 KEY BUYING CRITERIA OF ALLERGY DIAGNOSTICS AND TREATMENT MARKET
Figure 19 THE UNITED STATES ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 20 CANADA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 21 PERCENTAGE OF PEOPLE SUFFERING FROM SEVERE FOOD ALLERGY IN CANADA 2017
Figure 22 GERMANY ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 23 FRANCE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 24 THE UNITED KINGDOM ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 25 RUSSIA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 26 REST OF EUROPE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 27 INDIA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 28 CHINA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 29 JAPAN ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 30 AUSTRALIA AND NEW ZEALAND ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 31 REST OF APAC ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 32 MIDDLE EAST AND AFRICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 33 LATIN AMERICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 1 GLOBAL ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 2 GLOBAL TREATMENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
Figure 3 GLOBAL TREATMENTS MARKET IN OVER THE COUNTER 2018-2026 ($ MILLION)
Figure 4 GLOBAL TREATMENTS MARKET IN ORAL 2018-2026 ($ MILLION)
Figure 5 GLOBAL TREATMENTS MARKET IN SPRAY 2018-2026 ($ MILLION)
Figure 6 GLOBAL TREATMENTS MARKET IN OCULAR 2018-2026 ($ MILLION)
Figure 7 GLOBAL TREATMENTS MARKET IN TOPICAL 2018-2026 ($ MILLION)
Figure 8 GLOBAL TREATMENTS MARKET IN ANTIHISTAMINES 2018-2026 ($ MILLION)
Figure 9 GLOBAL TREATMENTS MARKET IN SYMPATHOMIMETICS, DECONGESTANTS AND COMBINATIONS 2018-2026 ($ MILLION)
Figure 10 GLOBAL TREATMENTS MARKET IN CORTICOSTEROIDS 2018-2026 ($ MILLION)
Figure 11 GLOBAL TREATMENTS MARKET IN LEUKOTRIENES 2018-2026 ($ MILLION)
Figure 12 GLOBAL TREATMENTS MARKET IN MAST CELL STABILIZERS 2018-2026 ($ MILLION)
Figure 13 GLOBAL DIAGNOSTICS MARKET IN SKIN TESTING 2018-2026 ($ MILLION)
Figure 14 GLOBAL TREATMENTS MARKET IN ANTIBODY 2018-2026 ($ MILLION)
Figure 15 GLOBAL TREATMENTS MARKET IN SUBCUTANEOUS ADMINISTRATION 2018-2026 ($ MILLION)
Figure 16 GLOBAL TREATMENTS MARKET IN SUBLINGUAL LIQUID SOLUTIONS 2018-2026 ($ MILLION)
Figure 17 GLOBAL TREATMENTS MARKET IN SUBLINGUAL TABLETS 2018-2026 ($ MILLION)
Figure 18 KEY BUYING CRITERIA OF ALLERGY DIAGNOSTICS AND TREATMENT MARKET
Figure 19 THE UNITED STATES ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 20 CANADA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 21 PERCENTAGE OF PEOPLE SUFFERING FROM SEVERE FOOD ALLERGY IN CANADA 2017
Figure 22 GERMANY ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 23 FRANCE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 24 THE UNITED KINGDOM ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 25 RUSSIA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 26 REST OF EUROPE ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 27 INDIA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 28 CHINA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 29 JAPAN ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 30 AUSTRALIA AND NEW ZEALAND ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 31 REST OF APAC ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 32 MIDDLE EAST AND AFRICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
Figure 33 LATIN AMERICA ALLERGY DIAGNOSTIC AND TREATMENT MARKET 2018-2026 ($ MILLION)
